Skip to main content

Table 2 Overall Summary of AEs

From: Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

 

Bazedoxifene

Raloxifene

Placebo

Subjects, n (%)

20 mg

(n = 1886)

40 mg

(n = 1872)

60 mg

(n = 1849)

(n = 1885)

Any AE

1807 (95.8)

1792 (95.7)

1777 (96.1)

1814 (96.2)

Any serious AE

382 (20.3)

368 (19.7)

344 (18.6)

354 (18.8)

Discontinuations due to AE

278 (14.7)

280 (15.0)

273 (14.8)

253 (13.4)

AEs > 10% in any treatment group

    

   Back pain

607 (32.2)

591 (31.6)

602 (32.6)

616 (32.7)

   Arthralgia

594 (31.5)

574 (30.7)

601 (32.5)

580 (30.8)

   Pain

568 (30.1)

559 (29.9)

588 (31.8)

592 (31.4)

   Flu syndrome

489 (25.9)

481 (25.7)

512 (27.7)

509 (27.0)

   Infection

462 (24.5)

433 (23.1)

439 (23.7)

452 (24.0)

   Abdominal pain

409 (21.7)

413 (22.1)

448 (24.2)

456 (24.2)

   Accidental injurya

449 (23.8)

394 (21.0)

387 (20.9)

468 (24.8)

   Headache

432 (22.9)

446 (23.8)

417 (22.6)

443 (23.5)

   Hypertension

396 (21.0)

379 (20.2)

375 (20.3)

394 (20.9)

   Constipation

352 (18.7)

356 (19.0)

340 (18.4)

327 (17.3)

   Hot flushesb

238 (12.6)

244 (13.0)

223 (12.1)

119 (6.3)

   Cough increased

216 (11.5)

192 (10.3)

178 (9.6)

199 (10.6)

   Leg crampsa

207 (11.0)

205 (11.0)

221 (12.0)

156 (8.3)

   Asthenia

209 (11.1)

198 (10.6)

212 (11.5)

202 (10.7)

   Dyspepsia

192 (10.2)

169 (9.0)

178 (9.6)

195 (10.3)

   Peripheral edema

200 (10.6)

184 (9.8)

194 (10.5)

166 (8.8)

   Urinary tract infection

183 (9.7)

176 (9.4)

197 (10.7)

170 (9.0)

   Dizziness

193 (10.2)

171 (9.1)

165 (8.9)

187 (9.9)

   Diarrheac

165 (8.7)

209 (11.2)

211 (11.4)

182 (9.7)

  1. AE, adverse event.
  2. a P < 0.01; Chi-square test.
  3. b P < 0.001; Chi-square test.
  4. c P < 0.05; Chi-square test.